Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors
Latest Information Update: 03 Feb 2023
Price :
$35 *
At a glance
- Drugs Migoprotafib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Roche
- 16 Dec 2022 Status changed from active, no longer recruiting to completed.
- 21 Jul 2022 Planned End Date changed from 27 Jul 2022 to 22 Nov 2022.
- 21 Jul 2022 Planned primary completion date changed from 27 Jul 2022 to 22 Nov 2022.